Overview

Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB

Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Stage 1 proposed study will provide evidence to support the use of twice-daily dose 50mg DTG in children (20-35kgs) co-treated with RIF.
Phase:
Phase 4
Details
Lead Sponsor:
University of KwaZulu
Collaborator:
Centre for the AIDS Programme of Research in South Africa
Treatments:
Dolutegravir